Dynamics influence bacterial lysates in the treatment of infections lower respiratory tract infections in young patients
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
In practice family physician occupies an important position not only treat lower respiratory tract infections, and prevention and preventing the evolution of acute bronchitis in chronic bronchitis or chronic obstructive pulmonary disease.
The objective: to explore the dynamics specific vaccine effect of oral bacterial vaccine status indicators on the immune system in the treatment of recurrent bronchitis.
Materials and methods. During the period from November 2015 to July 2016 we carried out a survey and treatment of 51 patients aged 18 to 35 years, including 23 men (45,1%), 28 women (54,9%) living in Kiev area. All patients took place recurrent bronchitis. Of these, 27 patients received lyophilizate bacterial lysates: (Haemophilus infuenzae, Streptococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Streptococcus pyogenes and viridans, Moraxella catarralis) for 3 months.
Results. Noted a positive impact on performance immunomodulator phagocytosis function and level of T lymphocytes of the immune system fully only after 3 month Admission immunomodulator.
Conclusions. Complex therapy with an immunomodulator probably not affect the clinical picture regression bronchitis, because patients without long term adherence to treatment is not advisable to appoint iminomodulyator. Only with a 3 month use of immunomodulators in the treatment showed a decrease in recurrence rate of bronchitis.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Бережний В.В. / Педіатрія: національний підручник : у 2 т., Т. 1 / За ред. Професора В.В. Бережного. – К., 2013. – С. 69–77.
Горностаєва Ю.А. Справочник поликлинического врача. – 2007. – No 12. – С. 7–11.
Зайцев А.А., Кулагина И.Ц. Острый бронхит // Фарматека. – 2015. – No 14. – С. 92–97.
Игнатова Г.Л., Блиникова Е.В., Антонов В.Н. [и др.] Острый бронхит: влияние схемы терапии на течение заболевания // Русский Медицинский Журнал. – 2016. – С. 1–6.
Мухарлялов Ф.Ю., Сычева М.Г., Рассулова М.А. Пути снижения частоты обострений ХОЗЛ: противовоспалительная терапия, иммунорегуляторы, пульморебилитация // Лечащий врач. – 2016. – No 10. – С. 30–35.
Овчинникова А.Ю., Мирошниченко Н.А., Евдокимова А.И. Новые возможности оптимизации терапии кашля // Лечащий врач. – 2016. – No 10. – С. 5–9.
Ayrle H., Mevissen M., Kaske M. [et al.]. Medicinal plants – prophylactic and therapeutic options for gastroin testinal and respiratory diseases in calves and piglets? A systematic review // BMC Vet Res. 2016, Jun 6;12 (1): 89. DOI: 10.1186/s12917-016-0714-8.
Capetti A., Cossu M.V., Carenzi L., Rizzardini G. Four years of immunization with OM 85 BV to prevent respiratory infections in HIV+ patients // Human Vaccines & Immunotherapeutics. 2013; 9 (9): 1849 1851. DOI: 10.4161/hv.25104.
Puhan M.A., Yu T., Boyd C.M., TerRiet G. Quantitative benefit– harm assessment for setting research priorities: the example of roflumilast for patients with COPD // DMC Med. 2015, Jul 2; 13: 157. Epub 2015, Jul 2.
